Market Flux Event
Eli Lilly Partners With Hims & Hers to Sell Zepbound and Foundayo Directly Through Telehealth Platform
Read this in the Market Flux appEli Lilly has struck a direct-to-consumer distribution deal with Hims & Hers Health, allowing the telehealth platform to offer two of Lilly's FDA-approved GLP-1 weight-loss medicines at transparent self-pay prices. Under the agreement, Hims & Hers will list injectable Zepbound (tirzepatide) starting at $299 per month and oral Foundayo (orforglipron) starting at $149 per month, with patients able to complete consultations, obtain prescriptions and arrange home delivery entirely within the Hims & Hers platform.
The deal carries a notable competitive dimension: Hims & Hers has committed not to offer compounded copies of Lilly's GLP-1 medicines as part of the arrangement. That pledge directly addresses a friction point Lilly and other branded GLP-1 makers have faced as compounding pharmacies have proliferated during periods of drug shortage. By locking in a major telehealth distributor on those terms, Lilly moves to protect market share for its branded products.
Hims & Hers stock rose on the news, according to market reports. The partnership is also expected to pressure rivals, with analysts noting that Novo Nordisk and other GLP-1 competitors may look to forge similar digital pharmacy arrangements to defend their own positions in the rapidly expanding weight-loss drug market.
© AI-generated summary is provided by Market Flux
Sources
- Wallstengine$LLY & $HIMS STRIKE GLP-1 ACCESS DEAL Under the agreement, Hims & Hers will offer Lilly's FDA-approved obesity medicines directly through its platform, with self-pay prices starting at: • Foundayo (oral): $149/month • Zepbound (injection): $299/month Eligible patients can complete consultations, receive prescriptions and arrange home delivery without leaving the Hims platform. Hims & Hers has also committed not to offer compounded copies of Lilly's GLP-1 medicines.
- Business WirePulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
- TheTradeXchange$CANF - Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
- Seeking AlphaEmergent BioSolutions: A Turnaround Still Waiting For Consistent Execution
- ReutersLilly to sell obesity drugs directly on Hims & Hers site
- MarketsdayEli Lilly $LLY and Hims & Hers Health $HIMS Access Agreement - November 06, 2026 🔹 Eli Lilly $LLY partnered with Hims & Hers Health $HIMS to expand direct-to-consumer digital distribution for its flagship GLP-1 weight-loss portfolio. 🔹 The agreement integrates FDA-approved Zepbound (tirzepatide) and the newly launched oral GLP-1 Foundayo (orforglipron) directly onto the Hims & Hers Health $HIMS telehealth platform. 🔹 The partnership aims to broaden access to authentic weight-loss medications while offering a transparent self-pay option to curb unlicensed compounding alternatives. 🔹 Global pharmaceutical peers like Novo Nordisk $NVO are expected to evaluate expanded digital pharmacy partnerships to preserve market share across the expanding GLP-1 landscape. #EliLilly #HimsAndHers #GLP1 #Pharma #Telehealth #Investing #Markets
- Briefingcom$HIMS: Hims & Hers Health expands access to Lilly's obesity medicines through its platform, with self-pay pricing starting at $149 monthly.
- Newsfile_CorpBetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha Full Story: #BetterLifeBio $BETR.C #BETR.CA #BETRF #BETR001 #MentalHealthBusiness #MentalHealthInnovation #Neuroplasticity #NonHallucinogenic #Chemicals #Pharmaceutical #Medical
Show 7 more
- BarronsWhy Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
- BarronsonlineHims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant’s GLP-1s on its consumer platform.
- BPharmCatalyst$ETON reported preliminary ET-700 pilot study data showing better GI tolerability than GALZIN (8% vs. 67% adverse events, n=12/arm), but weaker copper absorption inhibition (12% vs. 46% reduction in hepatic uptake; placebo +11%). Eton plans to test faster-release formulations in 2027 to improve efficacy. Results from this four-week study in healthy volunteers remain preliminary. $INO $SPRY $BDMD $BDSX $ETON $INGN $ADVB $GTBP $EVGN robinhood:0x351f65928a40657c31f51bb543f8bb3844d123fa See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
- OpenOutcrier$HIMS (+8.8% pre) $LLY Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients
- Newsfile CorpPhio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
- InvestingIMUNON presents translational data from ovarian cancer trial
- BusinessLilly's new Hims deal marks a surprising rapprochement with a telehealth company the pharmaceutical giant previously distanced itself from over compounded weight-loss drugs